Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.89% | -5.12% | 12.52% | 7.37% | 4.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.89% | -5.12% | 12.52% | 7.37% | 4.32% |
| Cost of Revenue | -1.66% | 3.33% | 9.20% | 2.79% | -1.49% |
| Gross Profit | 5.99% | -12.25% | 16.10% | 12.69% | 11.95% |
| SG&A Expenses | 3.72% | 5.54% | 9.48% | 3.19% | 5.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 111.76% | -22.22% | -171.43% | 95.83% | -342.86% |
| Total Operating Expenses | 0.73% | 4.05% | 7.74% | 4.33% | -0.09% |
| Operating Income | 7.42% | -28.62% | 31.93% | 21.94% | 32.26% |
| Income Before Tax | 162.42% | -148.62% | -593.85% | 73.46% | -73.16% |
| Income Tax Expenses | 242.31% | -31.71% | 675.00% | 4,037.50% | -173.68% |
| Earnings from Continuing Operations | 152.51% | -158.89% | -606.49% | 3.53% | -65.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -102.14% | 1,550.00% | -487.50% | -17.14% | 748.48% |
| Net Income | 253.96% | -146.87% | -733.33% | 2.98% | 36.82% |
| EBIT | 7.42% | -28.62% | 31.93% | 21.94% | 32.26% |
| EBITDA | 2.25% | -23.40% | 20.98% | 10.93% | 16.06% |
| EPS Basic | 251.86% | -146.37% | -726.14% | 4.10% | 37.25% |
| Normalized Basic EPS | -45.42% | -23.78% | 38.81% | 35.06% | 189.64% |
| EPS Diluted | 245.40% | -147.46% | -750.00% | 3.85% | 38.10% |
| Normalized Diluted EPS | -46.41% | -22.69% | 40.54% | 35.06% | 189.64% |
| Average Basic Shares Outstanding | 1.34% | 1.07% | 1.07% | 1.16% | 0.72% |
| Average Diluted Shares Outstanding | 3.21% | -0.35% | -0.18% | 1.16% | 0.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |